Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 13/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.54 |
| ▸ | CASP1 | P29466 | 6/20 | 0.54 |
| ▸ | CASP7 | P55210 | 6/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.54 |
| ▸ | HPGD | P15428 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | BAP1 | Q92560 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29392482 | 1.00 | KDM4E (0.54) | KDM4EALDH1A1CASP1CASP7HSD17B10 | |
| SCHEMBL30195593 | 1.00 | KDM4E (0.54) | KDM4EALDH1A1CASP1CASP7HSD17B10 | |
| SCHEMBL30938378 | 0.95 | KDM4E (0.51) | KDM4EALDH1A1CASP1CASP7HSD17B10 | |
| SCHEMBL31634751 | 0.95 | KDM4E (0.51) | KDM4EALDH1A1CASP1CASP7HSD17B10 | |
| SCHEMBL30938395 | 0.95 | KDM4E (0.51) | KDM4EALDH1A1CASP1CASP7HSD17B10 | |
| SCHEMBL31634735 | 0.95 | KDM4E (0.51) | KDM4EALDH1A1CASP1CASP7HSD17B10 | |
| SCHEMBL30938430 | 0.93 | ALDH1A1 (0.55) | KDM4EALDH1A1CASP1CASP7HSD17B10 | |
| SCHEMBL31634750 | 0.93 | ALDH1A1 (0.55) | KDM4EALDH1A1CASP1CASP7HSD17B10 | |
| SCHEMBL30938403 | 0.93 | ALDH1A1 (0.55) | KDM4EALDH1A1CASP1CASP7HSD17B10 | |
| SCHEMBL30938391 | 0.93 | KDM4E (0.54) | KDM4EALDH1A1CASP1CASP7HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4691479-A2 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | Janssen Biotech, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4194548-B1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | JANSSEN BIOTECH INC (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20240417693-A1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | JANSSEN BIOTECH, INC. (US) | 2024-12-19 | — | — | US | disclosed |
| US-20240417692-A1 | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS INTO PANCREATIC ENDOCRINE CELLS USING HB9 REGULATORS | JANSSEN BIOTECH, INC. (US) | 2024-12-19 | — | — | US | disclosed |
| US-11981929-B2 | Use of small molecules to enhance MAFA expression in pancreatic endocrine cells | JANSSEN BIOTECH, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| US-11952591-B2 | Generation of human pluripotent stem cell derived functional beta cells showing a glucose-dependent mitochondrial respiration and two-phase insulin secretion response | JANSSEN BIOTECH, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| CN-117821369-A | Use of small molecules to enhance MAFA expression in pancreatic endocrine cells | 詹森生物科技公司 | 2024-04-05 | — | — | CN | disclosed |
| EP-4219683-A1 | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS INTO PANCREATIC ENDOCRINE CELLS USING HB9 REGULATORS | Janssen Biotech, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116286663-A | In vitro production of human pluripotent stem cell-derived functional beta cells | 詹森生物科技公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-4194548-A1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | Janssen Biotech, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| WO-2013112859-A1 | METHOD FOR ENHANCING REMYELINATION USING GLI1 INHIBITORS | NEW YORK UNIVERSITY (US) | 2013-08-01 | — | — | WO | disclosed |
| US-20120108630-A1 | Hedgehog Pathway Antagonists and Methods of Use | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108630-A1 | Hedgehog Pathway Antagonists and Methods of Use | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108630-A1 | Hedgehog Pathway Antagonists and Methods of Use | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-05-03 | — | — | US | disclosed |
| US-8119640-B2 | Hedgehog pathway antagonists methods of use | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119640-B2 | Hedgehog pathway antagonists methods of use | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119640-B2 | Hedgehog pathway antagonists methods of use | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110015201-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-20 | — | — | US | disclosed |
| US-20110015201-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-20 | — | — | US | disclosed |
| US-20110015201-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952591-B2 | Generation of human pluripotent stem cell derived functional beta cells showing a glucose-dependent mitochondrial respiration and two-phase insulin secretion response | SLC2A3, SLC2A2, SLC2A1 | KDM4E 3567/4885ALDH1A1 597/4885CASP1 3551/4885 |
| US-20110015201-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND METHODS OF USE | SHH, GLI1, SMO | KDM4E 1642/4885ALDH1A1 2525/4885CASP1 4561/4885 |
| US-20240417693-A1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | SLC2A3, SLC2A2, SLC2A1 | KDM4E 3567/4885ALDH1A1 597/4885CASP1 3551/4885 |
| US-20120108630-A1 | Hedgehog Pathway Antagonists and Methods of Use | SHH, GLI1, SMO | KDM4E 1642/4885ALDH1A1 2525/4885CASP1 4561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.